Net Loss per Share - Schedule of computation of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Numerator
Net loss	$ (37,952)	$ (35,333)
Less: Net loss attributable to noncontrolling interest	$ (21,218)	$ (25,841)
Antidilutive securities
Earnout Rights	17,500,000	17,500,000
Stock options granted under the 2022 Equity Incentive Plan	30,393,917	21,845,327
Restricted Stock Rights [Member]
Antidilutive securities
Unvested Restricted Stock Rights	779,856	2,312,356
Common Class A [Member]
Numerator
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Basic	$ (16,734)	$ (9,492)
Net loss Available To Class A ordinary Shareholders of ProKidney Corp., Diluted	$ (16,734)	$ (9,492)
Denominator
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Basic	128,976,366	60,951,721
Weighted average Class A ordinary shares or ProKidney Corp. outstanding, Diluted	128,976,366	60,951,721
Net loss per share attributable to Class A ordinary shares, Basic	$ (0.13)	$ (0.16)
Net loss per share attributable to Class A ordinary shares, Diluted	$ (0.13)	$ (0.16)
Antidilutive securities
ProKidney Corp. ordinary shares	129,536,121		128,054,417
Common Class B [Member]
Antidilutive securities
ProKidney Corp. ordinary shares	163,161,681	167,723,553	163,693,707